Clinical TrialMay 6, 2026, 07:02 AM
Eupraxia's EP-104GI shows improved EoEHSS sub scores in EoE trial
AI Summary
Eupraxia Pharmaceuticals announced the first release of EoEHSS sub score data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for Eosinophilic Esophagitis (EoE). The data, presented at Digestive Disease Week, showed improvements in both inflammatory (EoEHSS-i) and architectural/fibrotic (EoEHSS-a) sub scores across most cohorts at 12 and 36 weeks. The highest dose cohort (cohort 9) demonstrated the largest improvements, with over 90% in inflammation and over 83% in tissue architecture, consistent with previous symptom and endoscope scoring data.
Key Highlights
- EoEHSS sub scores for inflammation improved in all cohorts at 12 weeks (n=31) and 36 weeks (n=27).
- EoEHSS sub scores for tissue architecture (fibrosis) improved across most cohorts at 12 and 36 weeks.
- The highest dose (cohort 9) showed the largest improvements in both inflammatory and architectural sub scores.
- Cohort 9 demonstrated over 90% improvement in EoEHSS-i grade and stage at 12 and 36 weeks.
- Cohort 9 showed over 83% improvement in EoEHSS-a grade and stage at 12 and 36 weeks.
- The Phase 2b part of the RESOLVE trial is currently recruiting 120mg and 160mg doses.
- Top-line data from the Phase 2b RESOLVE trial is expected in Q4 2026.
Price Impact
More from EPRX